WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555468

CAS#: 334951-90-5

Description: BIBF0775 is an inhibitor of the transforming growth factor β receptor I (TGFβRI). X-ray structure analysis showed that BIBF0775 soaked into the kinase domain of TGFβRI.

Price and Availability

Size Price Shipping out time Quantity
50mg USD 650 2 weeks
100mg USD 1050 2 weeks
200mg USD 1750 2 weeks
500mg USD 2650 2 weeks
1g USD 3650 2 weeks
2g USD 5450 2 weeks
5g USD 8950 2 weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-20. Prices are subject to change without notice.

BIBF0775, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 555468
Name: BIBF0775
CAS#: 334951-90-5
Chemical Formula: C31H34N4O2
Exact Mass: 494.2682
Molecular Weight: 494.639
Elemental Analysis: C, 75.28; H, 6.93; N, 11.33; O, 6.47

Synonym: BIBF0775; BIBF-0775; BIBF 0775;

IUPAC/Chemical Name: (3Z)-N-Ethyl-2,3-dihydro-N-methyl-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indole-6-carboxamide


InChi Code: InChI=1S/C31H34N4O2/c1-3-34(2)31(37)24-14-17-26-27(20-24)33-30(36)28(26)29(23-10-6-4-7-11-23)32-25-15-12-22(13-16-25)21-35-18-8-5-9-19-35/h4,6-7,10-17,20,32H,3,5,8-9,18-19,21H2,1-2H3,(H,33,36)/b29-28-


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

Inhibition of transforming growth factor β (TGFβ) type I receptor (Alk5) offers a novel approach for the treatment of fibrotic diseases and cancer.


1: Roth GJ, Heckel A, Brandl T, Grauert M, Hoerer S, Kley JT, Schnapp G, Baum P,
Mennerich D, Schnapp A, Park JE. Design, synthesis, and evaluation of indolinones
as inhibitors of the transforming growth factor β receptor I (TGFβRI). J Med
Chem. 2010 Oct 28;53(20):7287-95. doi: 10.1021/jm100812a. PubMed PMID: 20919678.